Active Recalls on Cheese, Coca-Cola and More to Be Aware of Right Now
There are active recalls on Chomps Beef Sticks, Aldi cheese, Coca-Cola and more.
Many of these products were sold nationwide at Costco, Trader Joe's and other retailers.
Common recall causes include foreign matter contaminations and undeclared allergens.There are a slew of recalls you should be aware of at the moment. From brand-name favorite drinks to pantry staples sold at Costco and Trader Joe's, there are several products to check your kitchen for. Here's everything you need to know about the latest alerts.
Chomps recalled two classic flavors, according to the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS). This was due to a foreign matter contamination.
The recalled Chomps Original Beef Sticks were sold at retailers nationwide, including Costco locations in 22 states. Each recalled beef stick has a printed establishment number of 6220A and UPC of 856584004183. In addition, the sticks sold in 12-count packaging contain a UPC of 856584004763. The following lot codes are also printed on the individual sticks: 25016, 25017, 25018, 25020 or 25021.
Related: Chocolate Is Being Recalled Nationwide Due to Contamination—Here's What to Know
Some Chomps Original Turkey Sticks have also been added to the recall, all of which were sold individually and bear the UPC of 856584004404 and a lot code of 25022 or 25023 on the individual stick package. Those sticks also have a printed establishment number of P6220A.
Two consumers reported finding metal fragments in the snack product, resulting in this recall. If you are experiencing any illness or injury after consuming these beef sticks, contact your doctor. For questions about this recall, call Chomps at 855-636-1150 from 8 a.m. to 8 p.m. CST or visit chomps.com/recall for more information.
Aldi just recalled cheese sold at locations in four states, according to the U.S. Food & Drug Administration (FDA). This is due to possible foreign matter contamination.
The recalled cheese is the Happy Farms by Aldi Colby Jack shredded cheese. Sold in 12-ounce plastic pouches, the recalled shredded cheese has a printed UPC of 4061463330840 and best-by dates of July 13 or 14, 2025. The cheese was sold at Aldi locations in Connecticut, Michigan, Ohio and Pennsylvania.
The recalled product may contain fragments of stainless steel in the shredded cheese, so check your refrigerator immediately for this product. If you have the recalled cheese on hand, return it to your local Aldi for a refund. For questions about this recall (or any recalls announced by the FDA), contact the FDA by calling 1-888-INFO-FDA (1-888-463-6332).
Related: These 7 Food Dyes Are Starting to Get Banned in States—Should You Still Eat Them?
There's an active recall on Coca-Cola soda cans sold in two states, per a recent FDA report. This is due to a foreign matter contamination as the drink may contain pieces of plastic.
The soda recalled were 12-ounce cans of Coca-Cola Original Taste sold in 12-count packs. There is a UPC of '0 49000-00634 6' printed on each can and a UPC of '0 49000-02890 4' printed on the packaging. Each can has a best-by date of September 29, 2025, and the cases were sold at retail locations in Illinois and Wisconsin.
Check your soda, and if it matches the recalled information, dispose of it or return it to your place of purchase for a possible refund.
Over 210,000 pounds of liquid egg products are being recalled right now, according to the FSIS. The recalled liquid eggs may have been in contact with cleaning products containing sodium hypochlorite.
The egg substitutes affected include multiple brands. Each of the following products are impacted and contain a printed establishment number of G1804 on the carton:
Egg Beaters Original Liquid Egg Substitute in 32-ounce cartons with a best-by date of August 10, 2025
Egg Beaters Cage-Free Original Liquid Egg Substitute in 32-ounce cartons with a best-by date of August 9, 2025
Egg Beaters Cage-Free Original Frozen Egg Substitute or Egg Beaters No Enjauladas Original Sutituto de Huevo Congelado in 32-ounce cartons with a best-by date of March 7, 2025
Bob Evans Better'n Eggs Made with Real Egg Whites in 32-ounce cartons with a best-by date of August 10, 2025
Check your refrigerator for these products. While there are no illnesses or injuries connected to this recall, be sure to contact your healthcare provider if you are experiencing any side effects. For questions pertaining to this recall, contact Chuck Miller, Cargill Kitchen Solutions, at 1-844-419-1574 or media@cargill.com.
Related: Over 12,000 Espresso Machines Recalled Nationwide Due to Burn Hazard
Trader Joe's latest recall is a popular bottle of salad dressing sold in 18 states and Washington, D.C. The product may contain multiple undeclared allergens.
The recalled salad dressing is the Trader Joe's Hot Honey Mustard Dressing packaged in 12-fluid-ounce bottles. Each recalled bottle has a printed SKU of 80152 and a use-by date of May 27, 2025. They were sold at Trader Joe's locations in the following states and district: Arkansas, Colorado, Delaware, Florida, Georgia, Kansas, Louisiana, Maine, Maryland, North Carolina, New Mexico, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia and Washington, D.C.
This salad dressing may contain peanuts, sesame, soy and wheat, all of which are common allergens that are not properly declared on the bottle. Those with allergies to these unlisted ingredients may experience an allergic reaction as serious as anaphylaxis. Common signs of anaphylactic shock include hives, difficulty breathing, abdominal pain, dizziness, tightness of the throat and in severe cases, cardiac arrest. Call 911 immediately if you have any of these symptoms after eating the recalled salad dressing.
Consumers with questions can contact Trader Joe's Customer Relations at (626) 599-3817 or by emailing via their product feedback form.
If you have a bag of Tostitos chips in your kitchen, you may want to check it for this recall information. Some 13-ounce bags of Tostitos Cantina Traditional Yellow Corn Tortilla Chips are being recalled right now, according to the FDA.
The yellow corn chips affected have a UPC of '28400 52848' and a 'guaranteed fresh' date of May 20, 2025. The recalled Tostitos products were sold at grocery stores, retail locations and drug stores in the following states: Alabama, Florida, Georgia, Illinois, Indiana, Kentucky, Mississippi, North Carolina, Ohio, South Carolina, Tennessee, Virginia and West Virginia. They may have also been sold online and shipped elsewhere.
The recalled chips may contain milk, a common allergen that is not declared on the product. This means that those with a milk allergy could be at risk of an allergic reaction such as anaphylaxis when eating these chips. Seek immediate medical attention if you are experiencing symptoms of anaphylactic shock after consuming this recalled snack.
If you have any questions or concerns regarding this recall, visit Frito-Lay's contact page or call the company at 1-800-352-4477 from 9 a.m. to 4:30 p.m. CDT, Monday through Friday.
Related: Nationwide Recalls on Frozen Meals, Coffee Creamers and More to Be Aware of Right Now
Read the original article on EATINGWELL
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
2 hours ago
- Business Upturn
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
By GlobeNewswire Published on August 7, 2025, 10:18 IST Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV. The FDA decision follows the announcement in July by the European Medicines Agency (EMA)1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough review of IXCHIQ® by its safety committee (PRAC). The PI has been updated to reflect reports of Serious Adverse Events, primarily among elderly individuals with multiple underlying health conditions, following a mass vaccination campaign in La Réunion in response to a severe chikungunya outbreak. The FDA noted that for most U.S. travelers the risk of exposure to CHIKV is low and therefore, the product is not advisable for most of them. IXCHIQ® should be given when there is a significant risk of chikungunya infection and only after careful consideration of the benefits and risks. Healthcare professionals are reminded that IXCHIQ® is contraindicated in individuals with weakened immune systems due to disease or immunosuppressive treatments, as stated in IXCHIQ®'s product label in the U.S., Europe and other territories. Furthermore, the product's Warnings and Precaution section has been expanded to reflect the SAE profile observed, especially in people above 65 years of age and older with one or more chronic medical conditions. Ongoing FDA reviews are progressing regarding potential extension of IXCHIQ®'s label to adolescents and inclusion of additional persistence data. About Chikungunya Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years2. In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas3. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas4 and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.5 About Valneva SEWe are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at Media and Investor Relations Contacts Laetitia Bachelot-FontaineVP Global Communications & European Investor RelationsM +33 (0)6 4516 7099 [email protected] Joshua Drumm, Global Investor RelationsM +001 917 815 4520 [email protected] Forward-Looking Statements This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as 'could,' 'should,' 'may,' 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'aims,' 'targets,' or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 1 Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted | European Medicines Agency (EMA) 2 3 4 PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas (Cumulative Cases 2018-2023 and Cases per year 2013-2017). . Last accessed 01 Aug 2023. 5 Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas ( Attachment 2025_08_07_FDA_UPDATE_IXCHIQ_PR_EN_FINAL_v3 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Business Insider
4 hours ago
- Business Insider
John Cena, 48, says getting this cosmetic procedure 'completely changed' his life
John Cena, 48, wrestled with hair loss for years, but this cosmetic procedure gave him his confidence back. In an interview with People published on Wednesday, Cena spoke about retiring from the WWE and the realities of aging, including his experience with hair loss. "As I was trying to hide my hair loss, the audience was bringing it to light," he told People. "I saw their signs that said 'The bald John Cena.'" The 17-time WWE world champion said the public scrutiny around his appearance "pushed him" to find ways to deal with hair loss. "I now have a routine: red-light therapy, minoxidil, vitamins, shampoo, conditioner — and I also got a hair transplant last November," Cena said. "I hate the fact that if there wasn't so much shame around it, I'd have gotten it done 10 years ago." The wrestler said he thought he was "alone" in his struggle, but eventually realized how common hair loss was among men. The procedure was simple, Cena said: "They don't do anything except move your hair, one by one, from one area to another." He added that he isn't embarrassed to talk about his hair transplant experience. "If somebody's going to sweat me for that, I don't think there's any shame in that," Cena said. "It completely changed the course of my life." As he looks beyond wrestling, he believes a fuller hairline might help him land a broader range of roles. "A different hairstyle can identify a part that can get me more work, do the thing I love to do," he added. A representative for Cena did not immediately respond to a request for comment sent by Business Insider outside regular hours. Male pattern baldness, or androgenetic alopecia, accounts for over 95% of hair loss in men, per data from the American Hair Loss Association, a nonprofit organization. Around 25% of men with male pattern baldness start losing hair before age 21. There are two FDA-approved medications for male pattern baldness, while other treatment options include laser therapy, platelet-rich plasma, and hair transplants. In recent years, Turkey has made a name for itself as the go-to destination for hair transplant surgery. Around one million people traveled to Turkey for hair transplants in 2022, the head of the Turkish Health Tourism Association told local news agency Anadolu. There's also been a trend of white-collar men in the US spending thousands on plastic surgery, fillers, and other self-care routines to look good, especially at work. Data from the 2023 American Society of Plastic Surgeons procedural statistics report showed that men accounted for 6% of cosmetic procedures overall. In 2023, facelifts among men rose by 17%, nose reshaping increased by 10%, and eyelid surgery increased by 9% compared to the previous year.
Yahoo
6 hours ago
- Yahoo
Becton, Dickinson and Company Submits Application to the FDA for a New, At-Home HPV Test
Becton, Dickinson and Company (NYSE:BDX) is one of the . On July 31, Becton, Dickinson and Company (NYSE:BDX) announced that it submitted an application to the U.S. FDA for a new, at-home HPV test. The new HPV test focuses on patients to self-collect a sample at their home using a swab, the size of a Q-tip, simplifying lab processing. According to BD, this method also reports more high-risk strains of HPV compared to other tests on the market today. A person wearing a state-of-the-art medical device for nerve conduction tests. 'We envision a world where women are empowered with access and a choice for their HPV screening, whether it be in a routine visit at the doctor's office or the comfort and privacy of their own home via a self-collected sample. Cervical cancer and the loss of more than 4,000 women per year to this devastating disease is preventable, and we believe at-home testing is an important leap forward to our goal of eliminating this type of cancer,' said Nikos Pavlidis, president of BD Diagnostic Solutions. BD's new HPV test will include a state-of-the-art self-collection swab technology that also offers convenient mailing from home to the lab, supporting broader participation in cervical cancer screening programs. The self-collected swab requires no manual sample preparation by clinical laboratory technologists. This process will allow them to focus on higher-value work. Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company that focuses on the development, manufacturing, and sale of various medical supplies, devices, diagnostic products, and laboratory equipment. While we acknowledge the potential of BDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio